3-Methylcholanthrene Anthracene Benzopyrene Black
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 3-Methylcholanthrene Anthracene Benzopyrene Black
- Multi-Component Mixture (Black Cohosh / Gelsemium / Thuja Complex): Insufficient Evidence for Repurposing Evaluation
Multi-Component Mixture (Black Cohosh / Gelsemium / Thuja Complex): Insufficient Evidence for Repurposing Evaluation
One-Sentence Summary
This submission describes a multi-component mixture containing herbal ingredients (Black Cohosh, Gelsemium sempervirens, Thuja occidentalis), inert excipients (silicon dioxide, sodium carbonate), and known research-grade polycyclic aromatic hydrocarbons (3-methylcholanthrene, anthracene, benzopyrene). The TxGNN model generated no predicted new indications for this compound, and the substance is not currently marketed in the United States. Without a DrugBank identifier, original approved indication, or any TxGNN prediction output, this candidate cannot proceed to standard repurposing evaluation at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indications on record) |
| Predicted New Indication | None generated by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why This Prediction Cannot Be Evaluated
This candidate presents three fundamental issues that prevent standard evaluation.
Composition concerns. The declared ingredient list includes 3-methylcholanthrene, anthracene, and benzo[a]pyrene — all polycyclic aromatic hydrocarbons (PAHs). Benzo[a]pyrene is classified as an IARC Group 1 human carcinogen; 3-methylcholanthrene is a potent experimental carcinogen routinely used in animal tumor-induction models. These are not recognised pharmaceutical active ingredients. Their presence in the ingredient string suggests either a data extraction error, a homeopathic dilution preparation (where ultra-low concentrations are claimed to reverse the toxic effect), or a research-use-only formulation. This ambiguity must be resolved before any safety or efficacy evaluation.
No DrugBank mapping. DrugBank returned 1 result (query_log ID 3), yet no DrugBank ID was successfully assigned. Without a validated DrugBank ID, the TxGNN knowledge graph cannot locate the drug node, which explains why zero predicted indications were returned. The herbal components (Black Cohosh, Gelsemium sempervirens, Thuja occidentalis) each have separate DrugBank entries; the mixture as a whole does not map to a single node.
No regulatory history. The compound has no US or Taiwan approved indication on record, no NDA, and no INN assignment. Gelsemium sempervirens root contains gelsemine and related alkaloids that are highly neurotoxic at pharmaceutical doses; any clinical development pathway would require explicit toxicological justification.
Safety Considerations
Given the composition of this mixture, the following safety signals are flagged based on known pharmacology of the components, even in the absence of formal safety data in the Evidence Pack:
- Benzo[a]pyrene and 3-methylcholanthrene: IARC Group 1 / Group 2A carcinogens. Genotoxic via covalent DNA adduct formation. No therapeutic dose range established.
- Gelsemium sempervirens: Contains strychnine-related alkaloids (gelsemine, sempervirine). Therapeutic window is extremely narrow. Toxic doses produce respiratory paralysis.
- Thuja occidentalis: Contains thujone (GABA-A antagonist). Convulsant in excessive doses; contraindicated in pregnancy.
- Black Cohosh: Associated with rare hepatotoxicity case reports. Phytoestrogenic activity may be relevant in hormone-sensitive conditions.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model could not generate predictions because the mixture lacks a valid DrugBank node mapping, and the ingredient list includes substances with no established pharmaceutical use and known serious toxicity (genotoxic carcinogens, neurotoxic alkaloids). Proceeding without resolving the identity and composition of this candidate would not be scientifically sound.
To proceed, the following is needed:
- Clarify the ingredient list origin — Determine whether the PAH components (methylcholanthrene, anthracene, benzopyrene) are present as actual pharmaceutical-grade active ingredients, homeopathic ultra-dilutions, or a data entry error.
- Assign a DrugBank ID — Map each active herbal ingredient individually (Black Cohosh → DB13941; Gelsemium sempervirens → separate DB entry; Thuja occidentalis → separate DB entry) and rerun TxGNN for each component independently.
- Obtain original indication documentation — If this is a marketed homeopathic or traditional medicine product, retrieve the product monograph or regulatory dossier to establish the claimed therapeutic category.
- Safety review for PAH components — If the carcinogenic PAHs are indeed present at any concentration, a formal genotoxicity and carcinogenicity risk assessment is mandatory before any human-use evaluation can begin.
- Re-submit as individual components — Consider splitting this multi-ingredient entry into separate TxGNN candidate runs, one per pharmacologically distinct herbal ingredient, to generate actionable predictions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.